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BACKGROUND & AIMS:FL
75
76
77There are few data on the incidence of upper and lower gastrointestinal bleeding (UGIB and
LGIB) from observational studies of low-dose aspirin users. We aimed to estimate incidence
rates of UGIB and LGIB in a large cohort of new users of low-dose aspirin in the United Kingdom,
with subanalyses of hospitalization status and fatalities.78
79METHODS:
80
81
82
83
84
85We performed a population-based study of 199,079 new users of low-dose aspirin (median age,
64.0 years) identified from the Health Improvement Network primary care database (2000–
2012). Individuals were followed for a median 5.4 years (maximum, 14 years) to identify new
cases of UGIB and LGIB. Following multistep validation, we calculated overall and age- and sex-
specific incidence rates; we performed subanalyses for health care use and death within 30
days of GIB. We also estimated rates within a matched (1:1) cohort of nonusers of low-dose
aspirin at the start of the follow-up period.86
87RESULTS:88
89
90
91
92
93
94
95
96The low-dose aspirin users had 1115 UGIB events and 1936 LGIB events; most subjects with
UGIB events (58.9%) were hospitalized, whereas most subjects with LGIB events were referred
to secondary care (72.8%). Crude incidence rates of GIB per 1000 person-years were 0.97 for
subjects with UGIB (95% CI, 0.91–1.02) and 1.68 for subjects with LGIB (95% CI, 1.60–1.75).
Incidence rates per 1000 person-years for hospitalized patients with GIB were 0.57 for UGIB
(95% CI, 0.53–0.61) and 0.45 for LGIB (95% CI, 0.42–0.49); for referred (but not hospitalized)
cases, these values were 0.39 for UGIB (95% CI, 0.36–0.43) and 1.22 for LGIB (1.16–1.29).
Incidence rates per 1000 person-years were 0.06 for fatal UGIB (95% CI, 0.04–0.07), 0.01 for
fatal LGIB (95% CI, 0.01–0.02), 0.91 for nonfatal UGIB (95% CI, 0.86–0.97), and 1.66 for nonfatal
LGIB (95% CI, 1.59–1.74). Among nonusers of low-dose aspirin, incidence rates per 1000
person-years were 0.67 (95% CI, 0.63–0.75) for UGIB and 0.76 (95% CI, 0.72–0.82) for LGIB.97
98CONCLUSION:99
100In a population-based study of low-dose aspirin users, the incidence of LGIB was higher than
the incidence of UGIB. However, patients with LGIB had higher rates of hospitalization or death
within 30 days than patients with UGIB. These estimates are valuable for benefit–risk assess-
ments of low-dose aspirin for cardiovascular and colorectal cancer prevention.101102
103Keywords: Observational Study; Ischemic Vascular Disease Prophylaxis; Major Bleeding; UK.104Abbreviations used in this paper: CI, confidence interval; CRC, colorectal
cancer; GI, gastrointestinal; EMR, electronic medical record; GIB,
gastrointestinal bleed; HES, Hospital Episode Statistics; LGIB, lower
gastrointestinal bleed; PCP, primary care practitioner; THIN, The Health
Improvement Network; UGIB, upper gastrointestinal bleed.
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116Low-dose aspirin is widely acknowledged to beeffective for ischemic vascular disease prophy-
laxis,1 and evidence also suggests a potential role in che-
moprevention, in particular for colorectal cancer (CRC),2,3
possibly mediated by platelet inhibition.4 Decisions to
prescribe prophylactic low-dose aspirin are based on
whether the clinical benefits are deemed to outweigh
the risk of major bleeding events, one of the most clini-
cally important being those of the gastrointestinal (GI)
tract. The balance of benefits and risks may vary with
age and other factors such as history of major bleeding.
While evaluation of low-dose aspirin should therebyA 5.5.0 DTD  YJCGH55912_proof  1consider age-specific frequencies of clinical events attrib-
utable to aspirin and patients’ clinical history, the severity
of these events and the potential for long-lasting disabling0 September 2018  11:45 am  ce OB
What You Need to Know
Background
There are few data on the incidence of upper
gastrointestinal bleed (UGIB) and lower gastrointes-
tinal bleed (LGIB) in the same population-based
cohort of low-dose aspirin users.
Findings
Among approximately 200,000 new users of low-
dose aspirin in primary care in the United
Kingdom, there were 3051 cases of GIB: 1115 UGIBs
and 1936 LGIBs. Incidence rates of UGIB and LGIB
per 1000 person-years were 0.97 and 1.68 among
users of low-dose aspirin and 0.67 and 0.76 among
matched nonusers of low-dose aspirin, respectively.
Implications for Patient Care
Our findings from an observational study of the
burden of UGIB and LGIB could help clinicians bal-
ance the benefits and actual risks of low-dose aspirin
use.
2 Cea Soriano et al Clinical Gastroenterology and Hepatology Vol. -, No. -
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232effects should also be considered—other factors that
could potentially shift the benefit–risk profile and influ-
ence prescribing decisions. GI bleeds (GIBs) vary in
severity, and although some may require hospitalization,
others may be less severe and be managed on an outpa-
tient basis. Importantly, discontinuation of low-dose
aspirin is not uncommon following an upper GIB
(UGIB)5 and is associated with an increased risk of cardio-
vascular events6 and death.7 Even minor bleeds, in any
part of the GI tract, could potentially lead to discontinua-
tion of prophylactic aspirin.
There are few studies from observational cohorts of
preventative low-dose aspirin users reporting incidence
rates for UGIBs,8–12 and even fewer for lower GIBs
(LGIBs).10,11,13 Furthermore, most have reported data only
for hospitalized events in individuals without GI ante-
cedents,10–13 and while separate estimates for fatal and
nonfatal GIBs are available from clinical trials,14 there are
few estimates from observational data.8 There is therefore
a need to obtain UGIB and LGIB incidence data, including
by age and bleed severity, among real-world low-dose
aspirin users, including those with previous GIBs or taking
concomitant medications known to increase bleeding risk.
Using a population-based cohort study in UK primary care,
we aimed to estimate the overall and age- and sex-specific
incidence of UGIB or LGIB among new users of low-dose
aspirin, with subanalyses by level of health care assis-
tance and case fatality.
Methods
Data Source
We used data The Health Improvement Network
(THIN), a validated UK population-based primary care
database containing anonymized electronic medical re-
cords (EMRs) ofw6% of the UK population and broadly
representative of its demographic.15,16 Participating pri-
mary care practitioners (PCPs) enter clinical information
using Read codes17 and free text; prescriptions are
recorded upon issue. Patient-level linkage to the Hospital
Episode Statistics (HES) database is possible for in-
dividuals in linked practices.18 Although low-dose
aspirin available over the counter in the United
Kingdom, most chronic aspirin use is via prescriptions
(free for individuals aged over 60 years),18 validation of
low-dose aspirin prescription data in THIN shows that
exposure misclassification owing to unrecorded over-
the-counter low-dose aspirin is likely to be minimal.19
An independent scientific review committee for THIN
reviewed and approved the study protocol (reference
number 14-088A1).
Identification and Follow-Up of the Study Cohort
A total of 199,079 new users of low-dose aspirin were
identified from THIN source population (N ¼ 1,840,253)FLA 5.5.0 DTD  YJCGH55912_proof  1(Figure 1) after applying inclusion and exclusion criteria
as described previously.20 The date of the first low-dose
aspirin prescription was designated the start date. Two
separate follow-ups of the cohort were undertaken: the
first to identify incident UGIB cases, the second to iden-
tify incident LGIB cases. Follow-up ended at the earliest
of the following: a Read code for UGIB or unspecified GIB
(UGIB follow-up) or Read code for LGIB or unspecified
GIB (LGIB follow-up), esophageal varices, coagulopathies,
chronic liver disease, alcohol abuse, cancer, age 90 years,
death, or December 31. 2013. Individuals with a Read
code for UGIB or unspecified GIB during the UGIB follow-
up (n ¼ 2721) and those with a Read code for LGIB or
unspecified GIB during the LGIB follow-up (n ¼ 10,473)
were identified as potential incident cases of UGIB or
LGIB. The index date was the date of the diagnostic Read
code.
Validation of UGIB and LGIB Cases
As summarized in Supplementary Figure 1, a multi-
stage process was undertaken to confirm the recorded
diagnosis of UGIB or LGIB or unspecified GIB, involving
at least 1 of the following validation processes: cross-
checking with cases validated in previous studies,21–24
linkage to HES data, and manual review of patient
EMRs including free-text comments and data mining
using text strings (see Supplementary Methods). Po-
tential incident UGIB or LGIB cases were considered
confirmed if there was evidence or referral to a
consultant or hospitalization. Cases of UGIB or LGIB
were subsequently classified by type of health care
assistance received either hospitalization or specialist
referral only (referred but not hospitalized). Cases with0 September 2018  11:45 am  ce OB
Figure 1. Flowchart
depicting the study
design. HES, Hospital
Episode Statistics; LGIB,
lower gastrointestinal
bleed; GIB, gastrointes-
tinal bleed; PCP, primary
care practitioner; THIN,
The Health Improvement
Network; UGIB, upper
gastrointestinal bleed.
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338a hospitalization in their EMRs within 15 days before
and 30 days after the GIB were assigned to the hospi-
talized group; remaining patients with a record of
referral were assigned to the referred group. For cases
without a hospitalization or referral, we manually
reviewed their EMRs to identify free text comments
implying hospitalization or referral. Cases who died on
or within 30 days following the index date were deemed
to be fatal cases irrespective of whether the primary
cause of death was due to the bleed itself or to associ-
ated comorbidities.339
340
341
342
343
344
345
346
347
348Covariates
Patient characteristics were ascertained at the start of
follow-up. In addition to demographics, we collected in-
formation on lifestyle variables (smoking status, alcohol
consumption and body mass index), comorbidities, and
health care use (number of PCP visits, referrals, and
hospitalizations). Lifestyle variables and comorbiditiesFLA 5.5.0 DTD  YJCGH55912_proof  1were ascertained any time before the start date, while
health care use was ascertained in the year before the
start date, using the most recent value or status. Medi-
cation use was ascertained on the start date or in the
prior 90 days.Statistical Analysis
Crude incidence rates per 1000 person-years with
95% confidence interval (CI) were calculated for UGIB
and LGIB separately, for all cases, and stratified by age,
sex, and GIB history. Incidence rates of UGIB and LGIB
were also calculated by the level of health care assistance
received (hospitalized or referred) and case fatality. In
an additional analysis, we estimated overall incidence
rates of UGIB and LGIB separately among a comparison
cohort of nonusers of low-dose aspirin. To identify this
cohort, each 199,079 new user of low-dose aspirin was
matched 1:1 to an individual from the THIN source
population (after applying all inclusion or exclusion0 September 2018  11:45 am  ce OB
Table 1. Baseline Characteristics of the Cohort of New Users
of Low-Dose Aspirin (N ¼ 199,049)Q5
Characteristics n %
Sex
Male 102,432 51.5
Female 96,617 48.5
Age
40–59 y 21,933 11.0
60–69 y 45,482 22.8
70–79 y 66,560 33.4
80–89 y 49,366 24.8
Smokinga
Nonsmoker 84,223 42.3
Current 41,137 20.7
Former 64,780 32.5
Unknown 8909 4.5
BMIa
15–19 kg/m2 5449 2.7
20–24 kg/m2 45,443 22.8
25–29 kg/m2 70,216 35.3
30 kg/m2 54,538 27.4
Unknown 23,403 11.8
Alcohola
None 34,578 17.4
1–9 u/w 88,133 44.3
10–20 u/w 30,222 15.2
21–41 u/w 10,521 5.3
42 u/w 2795 1.4
Unknown 32,800 16.5
Polypharmacyb
0–1 111,232 55.9
2–4 62,085 31.2
5 25,732 12.9
PCP visitsc
0–4 32,534 16.3
5–9 57,102 28.7
10–19 76,021 38.2
20 33,392 16.8
Referralsc
0–4 159,856 80.3
5–9 29,312 14.7
10–19 9036 4.5
20 845 0.4
Hospitalizationsc
None 154,871 77.8
1 27,058 13.6
2 10,773 5.4
3 6347 3.2
Comorbiditiesd
Intracranial bleed 1189 0.7
Ischemic stroke 9790 4.9
MI 17,023 8.6
IS 9790 4.9
TIA 7025 3.5
IHD (excluding MI) 19,768 9.9
Hypertension 95,934 48.2
Hypercholesterolemia 26,833 13.5
Diabetes 36,608 18.4
Atrial fibrillation 11,248 5.7
Heart failure 5367 2.7
PU, uncomplicated/complicated 10,092 5.1
Dyspepsia 38,584 19.4
Table 1. Continued
Characteristics n %
Comedicationse
Warfarin 3794 1.9
Clopidogrel 2855 1.4
NSAIDs 30,754 15.5
Insulin 6270 3.1
Oral antidiabetics 20,772 10.4
Antihypertensive agents 108,529 54.5
Statins 48,679 24.5
PPI 29,689 14.9
H2RA 5813 2.9
BMI, body mass index; H2RA, histamine-2 receptor antagonist; IHD, ischemic
heart disease; IS, ischemic stroke; MI, myocardial infarction; NSAID, nonste-
roidal anti-inflammatory drug; PCP, primary care practitioner; PPI, proton pump
inhibitor; PU, peptic ulcer; TIA, transient ischemic attack; u/w, units per week.
aAlcohol, BMI, and smoking were ascertained any time before the start date the
most recent status/value as appropriate.
bPolypharmacy was taken as the number of different medications in the month
before the start date.
cPCP visits, referrals and hospitalizations were ascertained in the year before
the start date.
dRecorded any time before the start of follow-up.
eUse on the start date or in the previous 90 days.
FLA 5.5.0 DTD  YJCGH55912_proof  1
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432criteria) free of low-dose aspirin on the aspirin user’s
start date.433
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461Results
Characteristics of the Study Cohort
Baseline characteristics of the low-dose aspirin study
cohort have been published previously.20 Briefly, the
median age of cohort members was 64.0 years (mean
63.9  10.8 years) and just over half were men (51.5%).
GI comorbidities recorded before the start of follow-up
were as follows: UGIB (0.9%), LGIB (5.6%), any GIB
(7.0%), uncomplicated peptic ulcer (3.8%), complicated
peptic ulcer (1.8%), dyspepsia (19.4%), and irritable
bowel disease (6.3%) (Supplementary Table 1). The
most common non-GI comorbidity was hypertension,
affecting 48.2% of the cohort. Use of medication among
cohort members (on the start date or in the previous 90
days) was as follows: nonsteroidal anti-inflammatory
drugs (16%), warfarin (1.9%), proton pump inhibitors
(14.9%), histamine-2 receptor antagonists (2.9%), and
clopidogrel (1.4%), while 7 patients were using direct
oral anticoagulants. Based on the computer algorithm,20
37% of the cohort had recorded cardiovascular ante-
cedents and were assumed to have received low-dose
aspirin for secondary prevention of ischemic vascular
disease. The remaining cohort members were assumed
to have received low-dose aspirin for primary prevention
purposes.0 September 2018  11:45 am  ce OB
462
463
464
Figure 2. Incidence rate of upper gastrointestinal bleed
(UGIB) and lower gastrointestinal bleed (LGIB) per 1000
person-years (with 95% confidence interval [CI]) among new
users of low-dose aspirin, by sex.
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544Incidence of UGIB and LGIB
A total of 3051 individuals in the study cohort (1.5%)
suffered a GIB over the follow-up period (median 5.4
years in both the UGIB and LGIB follow-up): 1115 inci-
dent cases of UGIB and 1936 incident cases of LGIB (4
individuals experienced both a UGIB and LGIB). The
overall crude incidence rate was lower for UGIB than for
LGIB: 0.97 cases per 1000 person-years (95% CI,
0.91–1.02) for UGIB and 1.68 cases per 1000 person-
years (95% CI, 1.60–1.75) for LGIB (Table 2). Incidence
rates were higher during the first year of follow-up: 1.31
per 1000 person-years (95% CI, 1.16–1.48) for UGIB and
1.95 per 1000 person-years (95% CI, 1.76–2.16) for
LGIB. Men had a higher incidence of UGIB than women
(1.03 vs 0.90 per 1000 person-years) while for LGIB,
incidence rates were slightly lower in men than women
(1.60 vs 1.76 per 1000 person-years) (Table 2; Figure 2).
Incidence rates of UGIB and LGIB increased with age,
with LGIB higher than UGIB in all age groups (Table 2,
Figure 3A; see Supplementary Table 2 for rates by 5-year
age stratification).Table 2. Incidence Rates of UGIB and LGIB per 1000 Person-
Years Among a Cohort of New Users of Low-Dose
Aspirin, Overall and by Sex, Age Group, Case
Fatality, and Level of Health Care Assistance
Cases
Person-
Years
Incidence
per 1000
Person-Years
(95% CI)
UGIB
Male 605 588,279 1.03 (0.95–1.11)
Female 510 566,971 0.90 (0.83–0.98)
Age 40–64 y 393 632,725 0.62 (0.56–0.69)
Age 65–74 y 378 348,673 1.08 (0.80–1.20)
Age 75–89 y 344 172,634 1.99 (1.79–2.21)
Fatal cases 64 1,154,032 0.06 (0.04–0.07)
Nonfatal cases 1051 1,154,032 0.91 (0.86–0.97)
Hospitalized cases 657 1,154,032 0.57 (0.53–0.61)
Referreda 452 1,154,032 0.39 (0.36–0.43)
Total 1115 1,154,032 0.97 (0.91–1.02)
LGIB
Male 941 588,281 1.60 (1.50–1.71)
Female 995 565,752 1.76 (1.65–1.87)
Age 40–64 y 889 632,725 1.41 (1.32–1.51)
Age 65–74 y 635 348,673 1.82 (1.68–1.97)
Age 75–89 y 412 174,170 2.39 (2.17–2.63)
Fatal cases 15 1,154,033 0.01 (0.01–0.02)
Nonfatal cases 1921 1,154,033 1.66 (1.59–1.74)
Hospitalized cases 523 1,154,033 0.45 (0.42–0.49)
Referreda 1410 1,154,033 1.22 (1.16–1.29)
Total 1936 1,154,033 1.68 (1.60–1.75)
NOTE. The number of hospitalized and referred (but not hospitalized) cases do
not sum the total number of cases for upper gastrointestinal bleed (UGIB) or
lower gastrointestinal bleed (LGIB) because 6 UGIB cases and three LGIB
cases were not referred or hospitalized but died at home.
CI, confidence interval.
aReferred but not hospitalized.
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580The majority of UGIB cases (58.9%) were hospitalized
whereas the majority of LGIB cases (72.8%) were
referred but not hospitalized. The incidence of hospital-
ized bleeds per 1000 person-years was 0.57 (95% CI,
0.53–0.61) for UGIB and 0.45 (95% CI, 0.42–0.49) for
LGIB, while the incidence of referred only bleeds per
1000 person-years was 0.39 (95% CI, 0.36–0.43) for
UGIB and 1.22 (95% CI, 1.16–1.29) for LGIB (Table 2,
Figure 3B). Corresponding incidence rates stratified by
age group are shown in Supplementary Table 3; inci-
dence rate ratios comparing rates in the 75–89-year age
group versus the 40–64-years age group were 1.3 for
hospitalized UGIB, 2.2 for referred only UGIB, 3.0 for
hospitalized LGIB, and 1.3 for referred-only LGIB.
Case-fatality rates were 5.7% (64 of 1115) for UGIB
and 0.8% (15 of 1936) for LGIB; 3.5% (16 of 452) for
referred UGIB, 6.4% (42 of 657) for hospitalized UGIB,
0.1% (2 of 1410) for referred LGIB, and 1.9% (10 of 523)
for hospitalized LGIB. For UGIB, the mean age of fatal
cases was 74.4 years (median 77.0 years) and for
nonfatal cases was 67.4 years (median 69 years). For
LGIB, the mean age of fatal cases was 78.1 years (median
79.0 years), and for nonfatal cases was 65.1 years (me-
dian 66.0 years). Incidence rates of fatal and nonfatal
UGIB per 1000 person-years were 0.06 (95% CI,
0.04–0.07) and 0.91 (95% CI, 0.86–0.97), respectively,
and for fatal and nonfatal LGIB they were 0.01 (95% CI,
0.01–0.02) and 1.66 (95% CI, 1.59–1.74), respectively
(Table 2, Figure 3C). Corresponding incidence rates
stratified by age group are shown in Supplementary
Table 4; incidence rate ratios comparing rates in the
75–89 year age group versus the 40–64 age group were
15.7 for fatal UGIB, 2.9 for nonfatal UGIB and 1.6 for
nonfatal LGIB (note, there were no fatal LGIB cases
among the younger age group).0 September 2018  11:45 am  ce OB
FLA 5.5.0 DTD  YJCGH55912_proof  1
6 Cea Soriano et al Clinical Gastroenterology and Hepatology Vol. -, No. -
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689The most frequent recorded GI antecedent among
UGIB cases was gastroduodenal mucosal lesions (29.3%),
followed by duodenal ulcer (20.1%) and gastric ulcer
(17.1%), with 26.7 of UGIB cases not having a reason for
their bleed recorded. For cases of LGIB, 43.4% of cases
previously presented with diverticular diseases, 12.1%
had polyps, and 8.0% had colitis, with 28.6% having no
recorded GI antecedent. The incidence of UGIB was 3.15
per 1000 person-years (95% CI, 2.22–4.48) for those
with a previous UGIB, was 1.68 per 1000 person-years
(95% CI, 1.33–2.11) for those with a previous uncom-
plicated peptic ulcer, and was 3.00 per 1000 person-
years (95% CI, 2.30–3.91) for those with a previous
complicated peptic ulcer. Among members of the study
cohort with a previous LGIB, the incidence of LGIB was
5.32 (95% CI, 4.77–5.94). For cohort members with an-
tecedents of ischemic vascular disease, incidence rates
were 1.20 (95% CI, 1.09–1.31) for UGIB and 1.80 (95%
CI, 1.68–1.94) for LGIB. Lower incidence rates were
among individuals without antecedents of ischemic
vascular disease: 0.84 (95% CI, 0.78–0.91) for UGIB and
1.61 (95% CI, 1.52–1.70) for LGIB.
Among the comparison cohort of nonusers of low-
dose aspirin at start of follow-up, the overall incidence
rates were 0.67 (95% CI, 0.63–0.75) for UGIB and 0.76
(95% CI, 0.72–0.82) for LGIB. The incidence rate ratio for
the aspirin vs comparison cohort was 1.42 (95% CI,
1.29–1.56) for UGIB and 2.17 (95% CI, 2.00–2.35) after
adjustment for age, sex, and number of PCP visits in the
year before the start date (Supplementary Table 5).
Discussion
In this large population-based study we have esti-
mated incidence rates of UGIB and LGIB among nearly
200,000 new users of preventative low-dose aspirin in
the United Kingdom after follow-up of up to 14 years. By
estimating incidence rates of both serious (hospitalized)
and nonserious (referred-only) UGIB and LGIB as well as
fatal and nonfatal cases in the same cohort, ours is the
first observational study to report on the actual burden
of all types of bleeding in the GI tract, and is thereby
helpful in appropriately balancing benefits and actual
risks of low-dose aspirin.
Case-fatality rates were low for both UGIB (6%) and
LGIB (<1%). Low case-fatality rates for GIBs have also
been shown among individuals randomized to low-dose
aspirin in clinical trials, especially among those without
ischemic vascular disease.14 Almost three-quarters of
LGIBs in our study did not require hospitalization, and
while the majority of UGIBs were hospitalized, a=
Figure 3. Incidence rate of upper gastrointestinal bleed
(UGIB) and lower gastrointestinal bleed (LGIB) per 1000
person-years (with 95% confidence interval [CI]) among new
users of low-dose aspirin, by (A) age group, (B) level of health
care assistance, and (C) case fatality.
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812substantial percentage (approximately 40%) were
managed as outpatients. Overall, the incidence of LGIB
was higher than UGIB in this study, which, based on
estimates from previous observational studies25 was
unexpected. A possible explanation is the use of acid-
suppressants such as proton pump inhibitors and
histamine-2 receptor antagonists (among approximately
18% of the cohort at start of follow-up) prescribed to
minimize UGIB in preventative aspirin users deemed
susceptible to bleeding. Another explanation is that most
previous studies addressed only hospitalized bleeds—in
terms of hospitalization rates, incidences of UGIB and
LGIB were similar in our study. Establishing patterns of
low-dose aspirin use among nonserious cases of
LGIB—in terms of levels of discontinuation, adherence,
treatment interruption, and medication switching—
would be of interest for study in further research.
Incidence of UGIB in this study is in line with that
found in a previous study in THIN of individuals using
low-dose aspirin for secondary prevention of ischemic
vascular disease.9 Incidence rates of hospitalized UGIB
and LGIB are slightly lower than those reported in large
U.S. observational cohorts of professional males10,13 and
females11 without previous GI bleeding or peptic ulcer
disease, who self-reported continuous use of preventa-
tive low-dose aspirin, although differences between UGIB
and LGIB incidence were similar. A higher incidence of
hospitalized UGIB was reported among low-dose aspirin
users in Denmark (3.64 per 1000 person-years) using a
prescription database and hospital discharge registry
records with data collected from 1991 to 1995.12
As expected by the low case fatality rates, the inci-
dence of fatal UGIB and LGIB in our study cohort was
substantially lower than the incidence of nonfatal events,
in line with data from aspirin randomized controlled
trials14 and observational data from secondary preven-
tion aspirin users.8 The absolute rate of fatal GIBs in
Elwood’s meta-analysis of randomized controlled trial
data was much higher at 0.37 per 1000 person-years
than in our study cohort; the incidence of all GIBs was
also substantially higher, at 8 cases per 1000 person-
years.14 Difference between individuals in our study
population and participants in the trials in the meta-
analysis could at least partly explain this difference; for
example, in our study, 63% of the study aspirin cohort
did not have recorded antecedents of ischemic vascular
disease. Fatal cases of UGIB and LGIB in our study cohort
were older than nonfatal cases, and overall incidence
rates of both bleeds increased with age, as seen in pre-
vious studies.8,9 In the Oxford vascular study, conducted
over the same time period as our study but among in-
dividuals receiving antiplatelet drugs following an
ischemic vascular event (mainly aspirin based), the rate
of significant nonmajor UGIB was approximately 2-fold
higher among the aged 75-years group vs those aged
<75 years.8 For major nonfatal UGIB, the incidence
among the older age group was almost 4-fold higher, and
for fatal UGIB it was almost 7-fold higher. We alsoFLA 5.5.0 DTD  YJCGH55912_proof  1observed a higher UGIB incidence among elderly low-
dose aspirin users in our study compared with those in
the youngest age group (aged 40–64 years); a 16-fold
increase for fatal UGIB and a 3-fold increase for
nonfatal UGIB; however, age-related differences for LGIB
were much lower.
Our study has several strengths. First, the large size of
the study population from a database representative of
the UK demographic allowed the calculation of precise
and generalizable UGIB and LGIB incidence rates. Second,
our study cohort included individuals with prior GI
comorbidities and users of comedications that are known
to increase GI bleeding risk, as well as those with or
without ischemic vascular disease, thereby representa-
tive of UK patients using preventative low-dose aspirin.
Thirdly, survivor bias was removed by the inclusion of
only new users of low-dose aspirin. Fourthly, the recor-
ded UGIB or LGIB diagnoses were validated through a
multistep process, including linkage to hospitalization
data or through manual review of patient records in
THIN including the free text comments. Previous vali-
dation studies using questionnaires to PCPs as the gold
standard have shown UGIB and LGIB Read codes in THIN
to have PPVs of 95% and 82%, respectively21–24 after
manual review of medical records incorporating free text
comments. A limitation of our study is that misclassifi-
cation of low-dose aspirin could have occurred from in-
dividuals discontinuing their preventative treatment
during follow-up—in censoring follow-up at 1 year after
start of therapy, GI bleeding rates were slightly higher.
Another limitation of our study is that we were unable to
separate GIB-specific mortality from mortality related to
underlying comorbidity because information on cause of
death is not available in the THIN. It is also possible that
there may have been some overestimation of hospital-
ized events. While our reasonably wide time window to
identify hospitalized bleeds minimized the potential for
missing hospitalizations related to the GIB itself,
including admissions that may have been related to other
conditions will have led to some overestimation of hos-
pitalized bleeds. However, the level of such misclassifi-
cation is likely to be small because we manually
reviewed patient records and it was often clear when a
particular hospitalization was related or unrelated to the
bleeding event itself. Long-term use of low-dose aspirin
is recommended for all patients with established
ischemic vascular disease. It is also recommended for
certain groups of patients without established ischemic
vascular disease but who are considered at high enough
risk—predominantly on the basis of age, vascular disease
risk score, and risk of bleeding—to warrant prophylactic
drug use.26–28 Recommendations in this latter group
have been informed by the accumulation of evidence
regarding the effectiveness of low-dose aspirin in
reducing CRC incidence and mortality and probably
some other cancers. With possibly increasing numbers of
individuals considered eligible to use low-dose aspirin,
accurate estimates of benefits and harms are required in0 September 2018  11:45 am  ce OB
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887general populations. A complete benefit–risk evaluation
of low-dose aspirin requires estimates of the absolute
excess reduction of ischemic vascular events and CRC
and the absolute excess increase of all major bleeds
(UGIB, LGIB, and intracranial bleed) in the same real-
world population that are attributable to the use of
low-dose aspirin, together with an appreciation of the
severity of these events and potential for long-lasting
disability.
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1160Case Inclusion Criteria
For upper gastrointestinal bleed (UGIB), the bleeding
or perforation site was required to be the stomach or
duodenum (patients with esophageal bleeding/perfora-
tion were excluded); for lower gastrointestinal bleed
(LGIB), bleeding was required to be in the jejunum,
ileum, colon, or rectum (bleeds due to hemorrhoids or
anal fissures were excluded).
Step 1: We identified individuals who had been
confirmed as either an incident case of UGIB (n ¼ 599),
LGIB (n ¼ 143), or a noncase (n ¼ 308) during previous
research projects in The Health Improvement Network
(THIN).1–4
Step 2: Among the remaining potential cases who
could not be cross-linked to previous projects (n ¼ 1920
in the UGIB follow-up, n ¼ 10,224 in the LGIB follow-up),
we identified those belonging to general practices linked
to Hospital Episode Statistics (n ¼ 657 [34.2%] in the
UGIB follow-up, 3544 [34.7%] in the LGIB follow-up).
Automated computer searches were performed among
these individuals’ HES records for International Classifi-
cation of Diseases-Tenth Revision ICD-10 codes for a GI
bleed during the study period and up to 90 days after,
and for all hospitalizations within 90 days before and
after the date of the GI bleed Read code in the THIN.
From this process, we identified 332 confirmed UGIB
cases, 544 confirmed LGIB cases and 213 confirmed
cases of a GI bleed with unspecified site (upper/lower;
all hospitalized). To complete the assignment of the site
of the bleed for this latter group (n ¼ 213), we manually
reviewed their medical records in the THIN, including
free text comments while masked to all medication use.
Step 3: Among all remaining unconfirmed cases, we
identified 10,649 individuals who were identified during
both the UGIB and LGIB follow-ups and removed any
duplicates (eg, those with a Read code for an unspecified
GI bleed on the same date in both follow-ups). After this
process, 9753 individuals remained as unconfirmed
cases of UGIB or LGIB.
Step 4: To assign case status to these 9753 in-
dividuals, we looked for indicators such as GI pro-
cedures, and specific symptoms entered in the
database within the 90 days before and 30 days after
the recorded date of the GI bleed to imply probable,
nonprobable, or still unknown case status. For
example, Read codes indicative of a probable case
included those for relevant GI antecedent, such as
diverticulosis, while codes suggestive of a nonprobable
case included those for digestive malignancies, hem-
orrhoids, and anal fissure. From this process, among
the 9753 potential cases there were 2590 probableFLA 5.5.0 DTD  YJCGH55912_proof  1cases, 1247 nonprobable, and 5916 remaining (no in-
formation from Read codes in their medical records to
help assign case status).
Manual Review of a Subset. Among these 9753 po-
tential incident cases, the medical records in the THIN
with free text comments (already available from previ-
ous research studies) of a subset of 767 individuals (190
deemed probable cases, 185 deemed nonprobable cases,
and 392 deemed remaining cases) were manually
reviewed (masked to all information on medication use)
and their case status ascertained. Among this subset of
767 patients, we calculated the positive and negative
predictive value or specific Read codes and applied these
predictive values to the 8986 potential incident cases not
included in this subset (ie, those without free comments
available in their medical records to review). Negative
predictive values for certain Read codes for rectal
bleeding, rectal hemorrhage, and bleeding per rectum
were >90% among the 185 nonprobable cases and
>84% among the 392 remaining patients manually
reviewed, and thus we searched for these codes among
all nonprobable and remaining patients not included in
the manually reviewed sample and excluded those with
these codes. Positive predictive values of various Read
codes were found to be heterogeneous in value and not
sufficiently high or low to help confirm case status. After
this process, there was still a total of 2400 of 2590
probable cases, and 854 of 5524 ‘remaining’ patients
without an assigned case status; all 1062 nonprobable
cases and 4670 patients in the ‘remaining’ group not
manually reviewed had an assigned case status (ie, all
were deemed noncases and were discarded owing to
having a high NPV Read code).
Use of Specific Read codes or Free Text Strings. Last,
for all individuals with a case status still unconfirmed
(n ¼ 3254), we applied a manual review process of their
THIN medical records, including free text comments
(while masked to medication exposure), to assign case
status and identify the site of the bleed (UGIB or LGIB).
To do this, we used the presence of specific Read codes
or text strings within the free text comments, within 1
year either side of the index date. For example, in-
dividuals with a code for hematemesis were classed as
having UGIB, as were those with a Read code for
gastrointestinal bleeding together with text involving
duodenal, hematemesis, gastritis, and coffee ground
detected in the free text comments. Similarly, individuals
with a Read code for gastrointestinal bleeding together
with text involving divert, colitis, or Crohn detected in the
free text comments, were assigned as having LGIB.
After this process, there were a total of 1115
confirmed UGIB cases and 1936 confirmed LGIB cases).0 SepReferences
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Supplementary Figure 1. Flow chart depicting the identification and validation of incident cases of upper gastrointestinal
bleed (UGIB) and lower gastrointestinal bleed (LGIB). EMR, electronic medical record; GIB, gastrointestinal bleed; HES,
Hospital Episode Statistics, ICD-10, International Classificiation of Diseases-Tenth Revision; THIN, The Health Improvement
Network.
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Supplementary Table 2. Crude Incidence Rates of UGIB and
LGIB per 1000 Person-Years
Among New Users of Low-Dose
Aspirin Stratified by 5-Year Age
Group
Age Group
Incidence Rate (95% CI) per 1000
Person-Years
UGIB LGIB
40–44 y 0.42 (0.27–0.63) 1.14 (0.88–1.46)
45–49 y 0.53 (0.40–0.72) 1.20 (0.98–1.47)
50–59 y 0.65 (0.52–0.82) 1.32 (1.13–1.54)
55–59 y 0.59 (0.48–0.72) 1.43 (1.26–1.63)
60–64 y 0.71 (0.61–0.84) 1.58 (1.42–1.75)
65–69 y 0.93 (0.80–1.08) 1.77 (1.59–1.98)
70–74 y 1.26 (1.10–1.45) 1.88 (1.68–2.10)
75–79 y 1.87 (1.63–2.14) 2.31 (2.05–2.62)
80–85 y 2.21 (1.87–2.61) 2.52 (2.15–2.94)
CI, confidence interval; LGIB, lower gastrointestinal bleed; UGIB, upper
gastrointestinal bleed.
Supplementary Table 1. Gastrointestinal Comorbidities of the Study Cohort (New Users of Low-Dose Aspirin) at the Start of
Follow-Up
Characteristic
Primary Prevention Users
(n ¼ 126,072, 63.3%)
Secondary Prevention Users
(n ¼ 72,977, 36.7%)
All New Users of low-Dose Aspirin
(N ¼ 199,049)
Any GI bleeda 8511 (6.8) 5403 (7.4) 13,914 (7.0)
UGIB 983 (0.8) 903 (1.2) 1886 (0.9)
LGIB 7136 (5.7) 4096 (5.6) 11,232 (5.6)
Complicated peptic ulcerb 1834 (1.5) 1674 (2.3) 3508 (1.8%)
Uncomplicated peptic ulcerb 3892 (3.1) 3704 (5.1) 7596 (3.8)
IBD 1368 (1.1) 950 (1.3) 2318 (1.2)
Dyspepsia 23,012 (18.3) 15,572 (21.3) 38,584 (19.4)
GI, gastrointestinal; IBD, irritable bowel disease; LGIB, lower gastrointestinal bleed; UGIB, upper gastrointestinal bleed.
aIncludes patients that had at least one episode of a previous GIB Any time before the start date taking the most recent value or status.
bComplicated peptic ulcers were events that presented with hematemesis or perforation, unlike uncomplicated peptic ulcer events.
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Supplementary Table 4. Crude Incidence Rates of UGIB and LGIB per 1000 Person-Years Among New Users of Low-Dose
Aspirin by Case Fatality and Stratified by Age Group
Age Group
Incidence Rate (95% CI) per 1000 Person-Years
UGIB LGIB
Fatala Nonfatal Fatala Nonfatal
40–64 y 0.014 (0.007–0.027) 0.61 (0.55–0.67) — 1.41 (1.32–1.50)
65–74 y 0.049 (0.030–0.078) 1.04 (0.93–1.15) 0.012 (0.004-0.031) 1.81 (1.67–1.96)
75–89 y 0.22 (0.160–0.30) 1.77 (1.58–1.98) 0.064 (0.035-0.115) 2.32 (2.11–2.56)
CI, confidence interval; LGIB, lower gastrointestinal bleed; UGIB, upper gastrointestinal bleed.
aFatal ¼ death within 30 days.
Supplementary Table 3. Crude Incidence Rates of UGIB and LGIB per 1000 Person-Years Among New Users of Low-Dose
Aspirin by Level of Health Care Use and Stratified by Age Group
Age Group
Incidence Rate (95% CI) per 1000 Person-Years
UGIB LGIB
Hospitalized Referred Only Hospitalized Referred Only
40–64 0.31 (0.27–0.36) 0.31 (0.27–0.36) 0.30 (0.26–0.35) 1.11 (1.02–1.19)
65–74 0.68 (0.60–0.78) 0.40 (0.34–0.47) 0.50 (0.43–0.58) 1.32 (1.21–1.45)
75–89 1.29 (1.13–1.47) 0.67 (0.59–0.81) 0.91 (0.78–1.06) 1.46 (1.29–1.65)
CI, confidence interval; LGIB, lower gastrointestinal bleed; UGIB, upper gastrointestinal bleed.
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Supplementary Table 5. Crude Incidence Rates of UGIB and
LGIB per 1000 Person-Years in the
Comparison Cohort of Nonusers of
Low-Dose Aspirin at Start of
Follow-Up
UGIB LGIB
Cases 728 827
Median person-years 5.20 5.20
Total person-years 1,079,283 1,079,302
Incidence rate (95% CI) per 1000
person-years
0.67 (0.63–0.75) 0.76 (0.72–0.82)
IRR (95% CI) of low-dose aspirin
vs comparison cohorta
1.42 (1.29–1.56) 2.17 (2.00–2.35)
CI, confidence interval; IRR, incidence rate ratio; LGIB, lower gastrointestinal
bleed; UGIB, upper gastrointestinal bleed.
aAdjusted by age, sex, and number of primary care practitioner visits in the year
before the start date.
FLA 5.5.0 DTD  YJCGH55912_proof  10 September 2018  11:45 am  ce OB
- 2018 GI Bleed Incidence in Low-Dose Aspirin Users 9.e6
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
